Inhibition of fatty acid amide hydrolase prevents pathology in neurovisceral acid sphingomyelinase deficiency by rescuing defective endocannabinoid signaling

Adrián Bartoll1†, Ana Toledano-Zaragoza1†, Josefina Casas2, Manuel Guzmán3, Edward H Schuchman4 & María Dolores Ledesma1,*

Abstract

Acid sphingomyelinase deficiency (ASMD) leads to cellular accumulation of sphingomyelin (SM), neurodegeneration, and early death. Here, we describe the downregulation of the endocannabinoid (eCB) system in neurons of ASM knockout (ASM-KO) mice and a ASMD patient. High SM reduced expression of the eCB receptor CB1 in neuronal processes and induced its accumulation in lysosomes. Activation of CB1 receptor signaling, through inhibition of the eCB-degrading enzyme fatty acid amide hydrolase (FAAH), reduced SM levels in ASM-KO neurons. Oral treatment of ASM-KO mice with a FAAH inhibitor prevented SM buildup; alleviated inflammation, neurodegeneration, and behavioral alterations; and extended lifespan. This treatment showed benefits even after a single administration at advanced disease stages. We also found CB1 receptor downregulation in neurons of a mouse model and a patient of another sphingolipid storage disorder, Niemann–Pick disease type C (NPC). We showed the efficacy of FAAH inhibition to reduce SM and cholesterol levels in NPC patient-derived cells and in the brain of a NPC mouse model. Our findings reveal a pathophysiological crosstalk between neuronal SM and the eCB system and offer a new treatment for ASMD and other sphingolipidoses.

Keywords endocannabinoids; neurodegeneration; Niemann–Pick; sphingomyelin

Subject Categories Genetics, Gene Therapy & Genetic Disease; Neuroscience; Pharmacology & Drug Discovery

DOI 10.15252/emmm.201911776 | Received 18 November 2019 | Revised 1 September 2020 | Accepted 14 September 2020

EMBO Mol Med (2020) e11776

Introduction

The endocannabinoid (eCB) system consists of a family of modulatory lipid messengers together with their specific receptors and metabolic enzymes. This cell signaling system regulates many aspects of neuronal development and function (Maccarrone et al., 2014) and influences synaptic communication in a plethora of physiopathological events, including cognitive and emotional processes (Katona & Freund, 2012; Mechoulam & Parker, 2013). Both anandamide (N-arachidonylethanolamine, AEA) and 2-arachidonoylglycerol (2-AG), the major eCBs, bind to the G protein-coupled receptors CB1 and CB2, of which CB1 is by large the most abundant in the brain (Pertwee et al., 2010). Both anandamide (N-arachidonylethanolamine, AEA) and 2-arachidonoylglycerol (2-AG), the major eCBs, bind to the G protein-coupled receptors CB1 and CB2, of which CB1 is by large the most abundant in the brain (Pertwee et al., 2010). Concertedly, the enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) contribute to the bulk of AEA and 2-AG degradation, respectively, and are essential for maintaining appropriate levels of both molecules (Di Marzo, 2009; Shin et al., 2019).

The neuromodulatory actions of eCBs are believed to rely on their release from a postsynaptic neuron upon stimulation and their subsequent retrograde action on presynaptic terminals, where they activate CB receptors, thus modulating plasma membrane ion conductivity and depressing neurotransmitter release (Castillo et al., 2012). CB1 receptor activation has been long related to inhibitory and excitatory synaptic plasticity underlying learning and memory (Sullivan, 2000; Domenici et al., 2006; Kawamura et al., 2006; Takahashi & Castillo, 2006). Alterations in the brain eCB system have been linked to various psychiatric conditions. For example, impaired AEA degradation underlies attention deficits and hyperactivity disorder (Centonze et al., 2009). It has also been proposed that endogenous CB1 receptor activation serves as a buffer against depression, while its downregulation results in depressive symptoms (Mangieri & Piomelli, 2007; Patel & Hillard, 2009; Fowler,
In addition, the eCB system plays important prohomeostatic, anti-inflammatory, and neuroprotective functions (Sarne & Mechoulam, 2005; van der Stelt & Di Marzo, 2005; Chiarlonre et al., 2014; Gomez-Galvez et al., 2016), and its possible involvement in different neurodegenerative diseases (van der Stelt et al., 2005; Blazquez et al., 2011; Aymerich et al., 2018) has stimulated the therapeutic interest of eCB modulation for the treatment of neurological disorders.

A series of previous studies point to the membrane environment as a critical factor for the regulation of the eCB system. For example, acute cholesterol depletion increases CB1-dependent signaling in neuronal cells (Bari et al., 2005a,b), and lipid raft-dependent and non-dependent endocytosis might be differentially involved in the transport of AEA and the axonal sorting of CB1 (McFarland & Barker, 2004; Leterrier et al., 2006; Fletcher-Jones et al., 2020). Moreover, eCBs are believed to bind to and activate CB1 receptors by lateral diffusion within the lipid bilayer, rather than reaching the binding site from the extracellular surface (Lynch & Reggio, 2006; Hua et al., 2017). These observations highlight the relevance of membrane lipids to eCB function and the need to understand in further detail their contribution.

The infantile, neurovisceral form of acid sphingomyelinase deficiency (ASMD also known as acute neuropathic ASMD or Niemann–Pick type A) is a fatal lipodysis that leads to hepatosplenomegaly, pulmonary involvement, impaired psychomotor development, and neurodegeneration (McGovern et al., 2017). Disease-causing mutations in the gene encoding ASM (SMPD1), a key enzyme responsible for SM degradation, induce the accumulation of this lipid in all body cells (Schuchman & Desnick, 2017). In neurons from ASM knockout (ASM-KO) mice, high SM levels in the lysosomes and the synaptic and plasma membrane lead to lysosomal permeabilization and autophagy impairment (Gambre-Rodriguez et al., 2014), unpolarized distribution of proteins (Galvan et al., 2008), dendritic spine anomalies (Arroyo et al., 2014), and Ca2+ imbalance (Perez-Canamas et al., 2016). Enzyme replacement therapy (ERT) by intravenous infusion of recombinant human ASM efficiently treats the non-neurological pathology in ASM-KO mice (Miranda et al., 2000) and in ASMD patients (Wasserstein et al., 2015). Two clinical trials (ASCEND and ASCEND-Peds) are currently ongoing (NCT02004691 and NCT02292654, respectively) for ASMD patients that lack neurological involvement (i.e., Niemann–Pick type B or chronic visceral ASMD) (McGovern et al., 2017). However, the inability of the recombinant enzyme to cross the blood–brain barrier and the absence of improvement in the neurological component after ERT in ASM-KO mice (Miranda et al., 2000) indicate that this approach would be inadequate for the neurovisceral forms.

In addition to ASM, there are other sphingomyelinases that are active in the mammalian brain and can degrade SM. Indeed, pharmacological enhancement of the neutral sphingomyelinase (NSM) by the glucocorticoid dexamethasone reduced SM levels in synapses of ASM-KO mice and improved their memory and learning capabilities (Arroyo et al., 2014). These findings pointed to the activation of NSM, an enzyme that is not genetically affected in ASMD, as a suitable strategy to diminish high brain SM levels in the disease. It has been shown that cannabinoid-evoked stimulation of CB1 receptors activates NSM through the adaptor protein FAN, thus reducing SM levels in cultured rat astrocytes (Sanchez et al., 2001). Early work in cultured fibroblasts from a severe ASMD patient also showed the capacity of cannabidiol to reduce SM levels (Burstein et al., 1984). We thus hypothesized that enhancing the activity of the eCB system in brain and peripheral organs could be therapeutically beneficial for patients with both the neurovisceral and visceral forms of ASMD. In this study, we provide proof of concept for this hypothesis by showing that (i) elevated SM leads to reduced CB1 expression and altered localization in neurons, (ii) there is a pathological downregulation of the eCB system in neurons of ASM-KO mice and of an infantile ASMD patient, and (iii) inhibitors of the eCB hydrolytic enzyme FAAH exhibit safety and efficacy to treat brain and peripheral pathology in ASM-KO mice. We also extend this concept to another sphingolipid storage disease, NPC, by showing CB1 receptor downregulation in a mouse model and a patient and that FAAH inhibition reduces SM and cholesterol levels in NPC patient-derived cells and in the brain of a NPC mouse model.

**Results**

**Characterization of CB1 receptor anomalies in the brains of ASM-KO mice and an infantile neurovisceral ASMD patient**

CB1 and CB2 receptors mediate eCB signaling in the mammalian brain. To determine whether these receptors are altered in ASM-KO mice, we measured their mRNA and protein levels in the brains of age-matched, 4-month-old WT and ASM-KO mice. We focused on the analysis of the cerebellum, which is the most affected brain area in the disease. Real-time quantitative PCR (RT-qPCR) showed no significant differences in the levels of CB2 mRNA (Fig 1A). Protein levels of this receptor were also unchanged as determined by Western blot in cerebellar extracts of ASM-KO mice compared to WT littermates (Fig 1B). In contrast, mRNA levels of CB1 were 30% diminished in the cerebellum (Fig 1C). Similar reductions (40 and 30%, respectively) were also found in other brain areas such as the hippocampus and prefrontal cortex (Appendix Fig S1A). Western blot of cerebellar extracts showed a slight 13% reduction in CB1 protein levels that was not statistically significant (Fig 1D). Similar results were found by Western blot of hippocampal and cortical extracts (Appendix Fig S1B). Slight decreases in CB1 protein levels were detected by immunofluorescence in these two brain areas (Appendix Fig S1C). To monitor the cell type specificity of CB1 protein expression, we performed co-labeling with cellular markers by immunofluorescence in the cerebellum. This analysis indicated a significant 26% reduction in the levels of CB1 protein in the Purkinje neurons, identified by calbindin staining, and a reduced co-localization between CB1 and these cells as indicated by the Mander’s coefficient, which reflects the amount of CB1 in this particular cell population with respect to the total CB1 staining in the tissue (Fig 1E). CB1-associated intensity was not significantly changed in astrocytes, identified by GFAP staining. However, the Mander’s coefficient between CB1 and astrocytes increased, probably due to the elevated number of these cells in the ASM-KO compared to WT cerebellum (Fig 1F and Appendix Fig S2A). CB1 levels and co-localization did not change in microglia, identified by F4/80 staining, which also increased their number in the ASM-KO cerebellum (Fig 1G and Appendix Fig S2B). These changes in the balance among cell populations in the ASM-KO mouse brains might prevent
Figure 1.
the detection of the neuronal-specific CB1 reduction in the biochemical experiments. To determine whether the reduction in CB1 protein levels observed in the Purkinje neurons of the ASM-KO mouse also occurred in patients, we gained access to fixed tissue from the cerebellum of a 3-year-old child affected by infantile neurovisceral ASMD and compared CB1 levels in the calbindin-positive cells by immunofluorescence with an age-matched unaffected child. CB1 protein was notably reduced in the Purkinje cells of the ASMD patient (Fig 1H). Reduction of CB1 levels was also observed in neurons (identified by MAP2 staining) of the medium bulb, the other brain area to which we had access in the ASMD patient (Appendix Fig S3). While these observations are not conclusive, since they were made in a single patient, they suggest common CB1 alterations in ASMD-affected humans and mice.

**High SM induces CB1 receptor reduction and misdistribution in ASM-KO neurons**

To further understand the impact of ASM deficiency on CB1 expression in neurons, the cell type in which we observed alterations in the tissue analysis (Fig 1), we analyzed CB1 levels and distribution in cultured primary neurons from WT and ASM-KO mice. CB1 mRNA levels were drastically reduced (95%) in the ASM-KO hippocampal neurons (Fig 2A). This was accompanied by a significant 66% reduction of CB1 protein levels measured by Western blot of neuronal extracts (Fig 2B). The immunofluorescence analysis also indicated a change in the distribution of CB1. Thus, while the receptor was preferentially lost from the neuronal processes (65% reduction), its localization in the lysosomal compartment (as...
Figure 2.
Figure 3.
visualized by the lysosomal marker Lamp1) increased in the ASM-KO neurons (Mander’s coefficient 0.15 and 0.33 in WT and ASM-KO neurons, respectively) (Fig 2C). A higher co-localization of CB1 with lysosomes was also observed in vivo in the Purkinje cells of the cerebellum of ASM-KO compared to WT mice (Mander’s coefficient 0.019 and 0.042 in WT and ASM-KO mice, respectively [Fig 2D]).

Sphingomyelin accumulation is a key pathological hallmark in ASM-KO neurons, which we confirmed in our hippocampal neuronal cultures (Fig 2E). To determine whether this was responsible for the aforementioned alterations in CB1 expression, cultured WT neurons were incubated with 40 μM SM for 48 h. These conditions increased SM to levels similar to those found in ASM-KO neurons (Fig 2F). SM addition produced a 60% decrease in CB1 mRNA, as measured by RT-qPCR (Fig 2G). CB1 protein levels were reduced from the neuronal processes (by 58%) and localization could be recovered in ASM-KO neurons by reducing its overall low levels due to increased degradation, we measured the amount of the protein in WT neurons incubated or not with 40 μM SM for 48 h in the presence or absence of the lysosomal inhibitor bafilomycin. This drug prevented by 61% the SM-induced CB1 reduction (Fig 2J). In a set of complementary experiments to those of SM addition to WT neurons, we diminished SM levels in cultured ASM-KO neurons by exogenous addition of sphingomyelinase. This treatment, which lowered SM levels by 46% (Fig 2K), resulted in a 55% increase in CB1 mRNA (Fig 2L). CB1 protein levels also increased by 45%, although this value was not statistically significant (Fig 2M). Immunofluorescence analyses showed the decreased co-localization of CB1 and Lamp1 upon sphingomyelinase treatment in the ASM-KO neurons (Mander’s coefficient 0.26 in non-treated cells and 0.15 in sphingomyelinase-treated cells; Fig 2N). This treatment induced reductions on the SM amount and CB1 mRNA levels, although not statistically significant, and no evident effect on CB1 protein levels in WT neurons (Appendix Fig S4).

Altogether, these data show that reduced expression of CB1 in ASM-KO neurons correlated with elevated SM and increased delivery of CB1 to lysosomes, leading to its degradation. CB1 expression and localization could be recovered in ASM-KO neurons by reducing SM levels.

eCB signaling reduces SM levels in cultured ASM-KO neurons

The reduced levels of CB1 observed in ASM-KO neurons, especially evident in the neuronal processes, and the reported ability of this receptor to activate NSM and hydrolyze SM in astrocytes (Sanchez et al, 2001) prompted us to assess the therapeutic potential of enhancing eCB action in ASMD. To this end, we first treated cultured ASM-KO neurons with different doses of AEA. This treatment reduced SM levels in a dose-dependent manner (Fig 3A). To determine whether NSM was involved in this effect, we treated ASM-KO neurons with AEA in the presence or absence of the NSM inhibitor GW4869. This compound blocked the effect of AEA on SM levels (Fig 3B). Also consistent with the contribution of NSM, we observed increased levels of this SM-degrading enzyme upon AEA treatment (Fig 3C). This treatment did not have significant effects on CB1 levels as assessed by Western blot (Appendix Fig S5A). Altogether, these observations point to the enhancement of eCB signaling as a potential intervention to increase NSM and reduce SM levels in neurons of ASM-KO mice and ASMD patients.

To boost eCB signaling in disease settings, selective inhibition of eCB degradation is currently being considered as a better therapeutic avenue than direct CB1 receptor agonism since the former avoids the psychoactive side effects of the latter (Di Marzo, 2008; Pertwee, 2012). Thus, we tested the ability of three different FAAH inhibitors (FAAHi) to reduce SM levels in ASM-KO neuronal cultures. Among the different currently available FAAHi, JNJ-1661010 (JNJ), PF-04457845 (PF), and URB-597 (URB) were chosen because they can readily cross the blood–brain barrier and have shown good tolerability in preclinical and clinical studies (Ahn et al, 2009, 2011; D’Souza et al, 2019). All three FAAHi reduced SM levels, an effect that was independent of the presence of AEA in the incubation medium (Fig 3D). URB treatment also resulted in significant elevation of CB1 protein levels (Appendix Fig S5B). The CB1 antagonist SR141716 (Rinaldi-Carmona et al, 1994) abrogated PF-induced SM reduction (Fig 3E) without altering CB1 levels (Appendix Fig S5C). Two parameters were monitored to rule out the toxicity of the treatments. First, the morphology of the neurons was determined by staining with the dendritic marker MAP2 and was not affected by
any of the treatments (Fig 3F). In addition, the number of apoptotic cells quantified by the TUNEL assay was not increased (Fig 3G). Incubation with AEA or the different FAAH inhibitors in the presence or absence of the NSM inhibitor or the CB1 antagonist did not have significant effects on SM levels in WT neurons (Appendix Fig S6). Overall, these findings demonstrate that activation of CB1 via FAAH inhibition in ASM-KO neurons leads to activation of NSM and degradation of SM without any associated cell toxicity.

Chronic oral treatment with the FAAHi PF improves behavior and extends lifespan in ASM-KO mice

The ability to reduce SM levels and the lack of toxicity of FAAHi in cultured ASM-KO neurons encouraged us to assess this strategy in vivo. Among the FAAHi used in vitro, we selected PF for in vivo studies owing to its high selectivity and efficacy, adequate oral bioavailability, optimal pharmacodynamic properties, and good

![Graphs A and B]

**Figure 4.**
treatment of the ASM-KO mice improved motor abilities and the elevated plus maze, suggesting increased anxiety (Fig 4E). PF (Fig 4D). ASM-KO mice also spent 11% less time in the open arm of the tail suspension test, which is indicative of a depressive state reported in ASM-KO mice. Specifically, the time that ASM-KO mice (Fig 4C). We also evaluated behavioral alterations not previously maze test, which measures hippocampal-dependent memory motor abilities (Fig 4B), and 62% less time in the new arm of the Y-maze test, which measures motor abilities (Fig 4B), and 62% less time in the new arm of the Y-maze test, which measures hippocampal-dependent memory (Fig 4C). We also evaluated behavioral alterations not previously reported in ASM-KO mice. Specifically, the time that ASM-KO mice spent moving was reduced by 55% compared to WT littermates in the tail suspension test, which is indicative of a depressive state (Fig 4D). ASM-KO mice also spent 11% less time in the open arm of the elevated plus maze, suggesting increased anxiety (Fig 4E). PF treatment of the ASM-KO mice improved motor abilities and increased the time in the new arm in the Y-maze (from 10% of the total time in the vehicle-treated ASM-KO mice to 23% in the PF-treated group), the mobility in the tail suspension test (from 53 to 95 s), and the time spent in the open arm in the elevated plus maze (from 14% of the total time in the vehicle-treated ASM-KO mice to 26% in the PF-treated group; Fig 4D and E). PF treatment in WT mice did not have significant effects in any of the tests analyzed (Fig 4B–E). These encouraging results obtained in behavior traits prompted us to extend PF treatment in a group of WT and ASM-KO mice in order to monitor survival. PF treatment increased life span by 31% in the ASM-KO mice (from 29 ± 2 weeks in vehicle-treated ASM-KO mice to 38 ± 2 weeks in the PF-treated group), without having any effect on WT mice survival (Fig 4F).

Chronic oral treatment with the FAAHi PF diminishes SM accumulation, lysosomal size increase, neurodegeneration, and inflammation in ASM-KO mice

Other groups of ASM-KO and WT mice were sacrificed after 8 weeks of PF treatment to monitor molecular and cellular hallmarks in different tissues. Mass spectrometry and HPLC showed increased

Figure 4. Chronic oral treatment with PF improves behavior and extends life span in ASM-KO mice.

A Weekly mean ± SEM body weight of WT and ASM-KO mice treated or not with PF (**P < 0.0001, n = 7 mice per group, statistics reflect the significant difference between the slope of the data in the PF-treated ASM-KO with respect to the other three groups; linear regression test).
B Mean ± SEM time spent on the rod in the 4 trials of the rotarod test by WT and ASM-KO mice after 2 months of vehicle or PF treatment (**P = 0.0488, *P = 0.361, n = 4 mice per group, two-way ANOVA, Bonferroni post hoc).
C Mean ± SEM time spent in the new arm of the Y-maze test by WT and ASM-KO mice after 2 months of vehicle or PF treatment (**P = 0.0024, *P = 0.0391, n = 9 mice per group, two-way ANOVA, Bonferroni post hoc).
D Mean ± SEM time of immobility in the tail suspension test of WT and ASM-KO mice after 2 months of vehicle or PF treatment (**P = 0.0198, *P = 0.0067, n = 6 mice per group, two-way ANOVA, Bonferroni post hoc).
E Mean ± SEM time spent in the open arms of the elevated plus maze by WT and ASM-KO mice after 2 months of vehicle or PF treatment (*P = 0.0342, n = 7 mice per group, two-way ANOVA, Bonferroni post hoc).
F Percentage of survival with respect to weeks of age in WT and ASM-KO mice treated with vehicle or PF (***P = 0.0031, n = 5 mice in WT vehicle, WT PF-treated and KO vehicle, 6 mice in KO PF-treated, Mantel–Cox).

Source data are available online for this figure.

Figure 5. Chronic oral treatment with PF reduces cellular and molecular pathology in ASM-KO mice.

A Mean ± SEM AEA levels in cerebellar extracts from WT and ASM-KO mice after 2 months of vehicle or PF treatment (**P = 0.0063, ***P = 0.0001, **P = 0.0001, *P = 0.0198, n = 4 mice per group, one-way ANOVA, Bonferroni post hoc).
B Mean ± SEM SM levels, expressed as percentage of vehicle values, in cerebellar extracts from WT and ASM-KO mice after 2 months of vehicle or PF treatment (**P = 0.0067, *P = 0.0465, n = 4 mice per group, one-way ANOVA, Bonferroni post hoc).
C Western blot against NSM and GAPDH (used as loading control) and graph showing mean ± SEM NSM protein levels in cerebellar extracts from WT and ASM-KO mice after 2 months of vehicle or PF treatment (n = 3 mice per group, one-way ANOVA, Bonferroni post hoc).
D Mean ± SEM CB1 mRNA levels in cerebellar extracts from WT and ASM-KO mice after 2 months of vehicle or PF treatment (**P = 0.0026, *P = 0.0345, n = 4 mice per group, one-way ANOVA, Bonferroni post hoc).
E Immunofluorescence against CB1 in Purkinje cells of the cerebellum of WT and ASM-KO mice after 2 months of vehicle or PF treatment. Graph shows mean ± SEM intensity associated with CB1, expressed as percentage of values in vehicle-treated mice (n = 4 mice per group, > 20 Purkinje cells per mouse, one-way ANOVA, Bonferroni post hoc). Scale bar, 10 μm.
F Immunofluorescence against CB1 and Lamp1 in the Purkinje cell layer of the cerebellum of WT and ASM-KO mice after 2 months of vehicle or PF treatment. Graphs show Mander’s coefficient for the co-localization of CB1 with Lamp1 (left) and mean ± SEM lysosomal size (right, ***P = 0.0002, **P = 0.0052, n = 4 mice per group, > 20 lysosomes per mouse, one-way ANOVA, Bonferroni post hoc). Scale bar, 5 μm.
G Immunofluorescence against the Purkinje cell marker calbindin in the cerebellum of WT and ASM-KO mice after 2 months of vehicle or PF treatment. Graph shows mean ± SEM number of calbindin-positive cells per area (**P = 0.0062, *P = 0.0001, n = 4 mice per group, one-way ANOVA, Bonferroni post hoc). Scale bar, 5 μm.
H Immunofluorescence against the astrocytic marker GFAP in the cerebellum of WT and ASM-KO mice after 2 months of vehicle or PF treatment. Graph shows mean ± SEM intensity associated with GFAP in arbitrary units (**P = 0.0001, *P = 0.0001, n = 4 mice per group, one-way ANOVA, Bonferroni post hoc). Scale bar, 10 μm.
I Immunofluorescence against the microglia marker Iba1 in the cerebellum of WT and ASM-KO mice after 2 months of vehicle or PF treatment. Graph shows mean ± SEM number (left) and area (right) of Iba1-positive cells (left: ***P = 0.0034, **P = 0.0001, right: ***P = 0.0001, *P = 0.00123, n = 4 mice per group, > 20 cells analyzed per mouse, one-way ANOVA, Bonferroni post hoc). Scale bar, 10 μm.

Source data are available online for this figure.
levels of AEA in the cerebellum of ASM-KO compared to WT mice and confirmed the ability of oral PF intake to increase the amount of AEA in cerebellar extracts of WT (3.2-fold increase) and ASM-KO (2.2-fold increase) mice (Fig 5A). PF treatment also reduced SM levels by 33% in the ASM-KO mice but not in the WT mice (Fig 5B). Western blot analysis showed a 42% enhancement of NSM...
expression in the cerebellar extracts of PF-treated compared to vehicle-treated ASM-KO mice, which was not observed in the PF-treated WT mice (Fig 5C). RT-qPCR analysis showed 10% increase in cerebellar CB1 mRNA (Fig 5D) and immunofluorescence analysis a 90% increase in CB1 protein levels in the Purkinje cells of the PF-treated compared to vehicle-treated ASM-KO mice (Fig 5E). Moreover, PF treatment limited the co-localization of CB1 with the lysosomal marker Lamp1 (Mander’s coefficient of 0.04 in vehicle-treated and of 0.02 in PF-treated ASM-KO mice) and reduced by 36% the size of the lysosomes in the Purkinje cells of the ASM-KO mice (Fig 5F). It also prevented the drastic loss (71%) of these cells in vehicle-treated ASM-KO mice by 31% (Fig 5G). Brain inflammation was analyzed by immunofluorescence against the astroglial marker GFAP and the microglial marker Iba-1. While GFAP-associated intensity was 80% higher in vehicle-treated ASM-KO compared to WT mice, PF treatment reduced this intensity by 45% (Fig 5H). While the number of microglial cells was increased by 200% in vehicle-treated ASM-KO compared to vehicle-treated WT mice, PF treatment diminished this value by 30% (Fig 5I). Likewise, the acquisition of amoeboid morphology, indicative of activated microglia, was prevented by PF as indicated by the 30% decrease in microglial area found in PF-treated compared to vehicle-treated ASM-KO mice (Fig 5I). PF treatment did not have significant effects in WT mice for any of the parameters analyzed, except for the aforementioned increment in AEA and CB1 levels (Fig 5).

To determine whether oral PF intake had any effect in peripheral organs, we measured SM levels in liver, spleen, and lungs, which are particularly affected in ASMD. PF treatment significantly reduced SM levels in the liver (35%) and spleen (30%). In lungs, we found a tendency to decrease of 25% (Appendix Fig S7). PF treatment had no effect on SM levels in the liver, spleen, and lungs of WT mice (Appendix Fig S7).

Safety of acute oral treatment with the FAAHi PF at late disease stages in ASM-KO mice

The findings described above demonstrate that chronic PF treatment of ASM-KO mice starting at early stages of the disease (6 weeks of age) ameliorates biochemical, cellular, and behavioral anomalies, and also extends life span. However, in the clinical setting it may be difficult to diagnose and start a treatment at such a young age, before substantial SM storage has occurred. Older patients are likely to have much higher levels of SM, and rapid hydrolysis of this lipid to its downstream products ceramide and sphingosine can be toxic (Testi, 1996; Teichgraber et al, 2008; Hagen et al, 2009; Murray et al, 2015). Therefore, to evaluate whether hydrolysis of high levels of SM by PF-induced activation of NSM might result in toxicity, we acutely treated 4-month-old ASM-KO and WT mice with a single PF administration by oral gavage at a similar dose to that used in the chronic study (0.1 mg/kg) or at 10 (1 mg/kg)- and 50 (5 mg/kg)-fold higher doses. No evident deleterious effects (i.e., death, lethargy, convulsions, weight, or hair loss) were observed during the following 48 h after administration of any of the doses.

At this time point, mice were sacrificed, and cell toxicity was analyzed by hematoxylin and eosin staining in different brain areas (cerebellum, hippocampus, and cortex), as well as in the liver. PF treatment at any dose did not promote cell loss in any of the tissues analyzed. The acute treatments also did not alter the presence of foam cells, which are characteristic of ASMD (Fig 6A). The absence of significant cell death was confirmed by cleaved caspase 3 staining of the tissues (Appendix Fig S8). Lipid assays showed that PF treatment for 48 h did not affect SM levels at the low and intermediate doses. A tendency to SM reduction was observed at the highest dose (5 mg/kg) that was statistically significant (16%) in the cortex (Fig 6B). Inflammation was analyzed by staining of microglia with Iba1 in the different brain regions and by staining of macrophages with F4/80 in the liver. Accumulation of microglia and increased macrophage area were evident in the tissues of ASM-KO compared to WT mice (Fig 6C). While the single PF administration at low and intermediate doses did not affect these parameters, administration of 5 mg/kg PF significantly reduced the number of microglia in the hippocampus and cortex, as well as macrophage area in the liver (Fig 6C). Single-dose administration of PF did not have overt effects in WT mice (Fig 6A–C). These results supported the safety of PF administration at advanced stages of the disease and revealed an effect on SM levels in the cortex after a single administration of high PF doses.

Downregulation of CB1 receptor and benefits of FAAHi treatment in NPC

Sphingomyelin accumulation also is a hallmark of other sphingolipid storage disorders including those with neurological involvement such as NPC (Lloyd-Evans et al, 2008). While the ASM gene, SMPD1, is not affected in NPC cells, they do exhibit deficient ASM activity that was corrected by recombinant ASM treatment or SMPD1 transfection. This, in turn, improved lipid (i.e., cholesterol) and protein trafficking defects (Devlin et al, 2010). To understand whether the impairment of eCB signaling is a shared pathological event between ASMD and NPC, and whether enhancement of this system could be considered as a common therapeutic strategy for this and potentially other sphingolipid storage disorders, we analyzed CB1 levels in the brain of an NPC mouse model and a patient, as well as the effects of FAAHi in NPC patient-derived cells and the NPC mouse model. As in the ASM-KO mice, we did not observe any significant reduction of CB1 protein levels by Western blot of cerebellar extracts in NPCcimH104 mice, which carry a point mutation in the npc1 gene and mimic NPC (Maue et al, 2012), compared to WT littermates (Fig 7A). However, immunofluorescence analysis showed a 32% reduction of the protein levels in the Purkinje cells of the NPCcimH104 mice (Fig 7B). Access to fixed tissue from the cerebellum of unaffected and NPC-affected children unveiled a 37% reduction in CB1 protein levels in the Purkinje cells of the NPC patient (Fig 7C). To determine the efficacy of FAAHi to reduce SM levels in the context of NPC, cultured fibroblasts from NPC patients were treated with 50 or 100 μM PF for 1 h. This intervention induced a dose-dependent reduction of SM levels (13 and 21% reduction, respectively; Fig 7D). Moreover, and consistent with the reported influence of SM reduction on cholesterol amount in NPC cells (Devlin et al, 2010), we observed a PF dose-dependent reduction on cholesterol levels (30 and 39% reduction, respectively; Fig 7E). In addition, PF treatment reduced the aberrantly increased CB1 localization in lysosomes in the NPC fibroblasts (Mander’s coefficient changed from 0.45 in the NPC vehicle-treated fibroblasts to 0.33 in the NPC PF-treated fibroblasts; Fig 7F). To determine the effects of FAAHi treatment in vivo, we
measured SM levels in the cerebellum of 3-month-old NPC

mice treated (or not) with a single, high dose (5 mg/kg) of PF for 48 h. This acute treatment diminished SM and cholesterol levels by 39 and 20%, respectively (Fig 7G). We did not observe a reduction in the number of microglia cells, which is increased in the cerebellum of vehicle-treated NPC compared to WT mice, but we detected a significant 25% decrease in the area of the microglia from this single treatment (Fig 7H).
Figure 7.
The results obtained in this study reveal multiple impacts of the eCB system in neurovisceral ASMD. On the one hand, the low levels of the CB1 receptor found in the neurons of ASM-KO mice and a severe ASMD patient suggest a pathological contribution of this system. On the other hand, the benefits obtained with a CB1 signaling-enhanced strategy in ASM-KO mice support the eCB system as a novel therapeutic target for this fatal disease.

The analysis of the eCB system in the context of a disease model characterized by SM accumulation uncovers a feedback loop between this lipid and eCB action. Cell-specific analysis revealed that, at least in ASMD, neurons are more susceptible to alterations in this feedback loop than astrocytes or microglia. This may also explain why the neuronal-enriched eCB receptor CB1 is preferentially affected compared to the glial (immune cell)-enriched eCB receptor CB2. Physiological amounts of SM at the neuronal plasma membrane are necessary to maintain not only the adequate levels of CB1 expression, but also its correct subcellular distribution. Aberrantly high SM amounts reduced both the mRNA and protein levels of CB1 in ASM-KO neurons, similar to what was observed in WT neurons treated with SM. Hence, we demonstrate the existence of a mechanistic link between SM levels and CB1 expression, which might be reciprocally complemented by a CB1-evoked reduction of SM levels through the activation of NSM, as previously described in astrocytes (Sanchez et al., 2001). This feedback loop would allow SM and CB1 to dynamically control each other’s levels. We also observed that high SM promotes the loss of CB1 from the neuronal processes and induces its accumulation in lysosomes. This may lead to an enhanced degradation of this receptor that would conceivably contribute to the low levels of CB1 protein found in ASM-KO neurons. CB1 sensitivity to membrane lipid changes had been previously illustrated by the effect of cholesterol depletion on CB1, but not CB2, signaling (Bari et al., 2005a,b). This effect was related to the specific presence of CB1, but not CB2, in lipid rafts (Bari et al., 2006; Maccarrone, 2008; Rimmerman et al., 2008). SM is, together with cholesterol, the main lipid component of rafts. Our findings thus reinforce the view that the composition of these membrane domains is a key factor for CB1 physiological actions and that this receptor contributes to regulate such composition through its influence on NSM. Another difference regarding the lipid sensitivity of CB1 and CB2 receptors is the interaction of the former, but not the latter, with sphingosine. In fact, this SM metabolite has been suggested as an endogenous ligand for CB1 (Paugh et al., 2006). CB1 undergoes constitutive internalization and recycling, which explains its movement between the plasma membrane and intracellular compartments (Leterrier et al., 2004; Fletcher-Jones et al., 2020). Exposure of CB1 to its agonists, for a prolonged time or at high concentrations, may promote the internalization of the receptor, the loss of its surface expression, and its exit from the recycling pathway to be targeted to lysosomes for degradation. This mechanism has been related to CB1 desensitization processes (Martini et al., 2007). It is possible that, in the context of ASMD, an increase in sphingosine due to SM accumulation, which has been indeed described in ASM-KO neurons (Camolotto et al., 2009), mediates the observed loss of CB1 from neuronal process and its enrichment in lysosomes.

The crosstalk between eCB action and different neurotransmission systems contributes to the modulation of glutamatergic and gabaergic signaling. This underlies eCB influence in various neurobiological processes, including cognition and emotion (Zimmermann et al., 2019). Particular attention has been given to the link between CB1 and members of the type 1 metabotropic glutamate receptor (mGluR) family. For example, stimulation of postsynaptic mGluR5 in the striatum enhances diacylglycerol lipase activity, leading to 2-AG production (Jung et al., 2007; Uchigashima et al., 2007). This eCB activates CB1 at the presynapses, thereby inhibiting synaptic transmission (Maccarrone et al., 2008; Lovinger, 2010). In a previous work, we have described mGluR5 deficiency in synapses of ASM-KO mice (Arroyo et al., 2014). This may also contribute to the low CB1 amounts described in the present study. Alterations in CB1 and mGluR5/2-AG coupling have been related with stress-induced anxiety and psychiatric defects in fragile X syndrome (Maccarrone et al., 2010; Busquets-Garcia et al., 2013; Chakrabarti et al., 2015). Future work will determine whether mGluR5/2-AG/CB1 uncoupling may occur in ASMD, and whether this is linked to the behavioral alterations we have observed in ASM-KO mice.
The eCB system also has important prohomeostatic and neuroprotective functions (Katona & Freund, 2012; Busquets-Garcia et al., 2013; Mechoulam & Parker, 2013). Alterations in eCB signaling have been related to different neurodegenerative diseases (van der Stelt et al., 2005; Blazquez et al., 2011; Gomez-Galvez et al., 2016; Aymerich et al., 2018), and hence, eCB modulation has gained therapeutic interest in recent years. Our findings link for the first time eCB system alterations with the lysosomal storage diseases, particularly those in which SM accumulates. Indeed, the abnormal down-regulation of eCB signaling in ASMD may explain some of the symptoms of this disease, such as sleep and body temperature disturbances or cognitive impairment. While treatment with exogenous cannabinoids can enhance eCB signaling, these compounds are likely to have psychotropic effects, risk of tolerance, and addiction, and are difficult to dose. Currently, pharmacological modulation of eCB regulatory enzymes is considered a safer and more suitable therapeutic avenue (Di Marzo, 2008; Pertwee, 2012). Specifically, inhibition of the eCB-degrading enzyme FAAH has been successfully tested in animal models for inflammation, chronic pain, and anxiety, without remarkable adverse effects (Kathuria et al., 2003; Russo et al., 2007; Ahn et al., 2009). Of note, eCB enhancement makes even more sense in the context of ASMD since the observed eCB hypofunction would diminish the risk of its pharmacological overactivation, which may have deleterious consequences. Moreover, we show that by enhancing CB1 function, we can counteract SM buildup, which is the main pathological hallmark in ASMD. All FAAHi tested in this study reduced SM levels in neuronal cultures with no evident toxicity. The in vivo oral administration of one of them (PF), at doses similar to those already used in healthy subjects (Ahn et al., 2011; Li et al., 2012), reduced SM content in brain and peripheral organs of ASM-KO mice and prevented motor, cognitive, and psychiatric alterations, as well as neuroinflammation and neurodegeneration. There was also a significant increase in survival. This evidence strongly supports the use of FAAHi as a new ASMD treatment.

Several considerations should be taken into account when treating infantile neurovisceral ASMD patients. First, the time window for therapeutic intervention is very short, as, although the disease may be diagnosed months after birth, it progresses very quickly and generally leads to death by 3 years of age (McGovern et al., 2017). It is important to emphasize that here, we started the chronic PF treatment in ASM-KO mice at 6 weeks of age, when SM levels are already elevated, and the first symptoms of the disease are evident. This reinforces the view that PF treatment would be beneficial even if started after the disease symptoms have already appeared. Second, the sudden conversion of the massive amount of accumulated SM at advanced stages of the disease into its proapoptotic and proinflammatory metabolites, including ceramide and sphingosine, is a potential hazard that has been observed in ASM-KO mice previously when high doses of recombinant ASM were used (Murray et al., 2015). The effects we found upon acute PF administration to 4-month-old ASM-KO mice argue against this possibility in our setting and support the safety of this compound even at very high doses (50-fold higher than the equivalent dose already used in human studies). Remarkably, our acute study also revealed some extent of efficacy even after a single administration of high doses. Third, a therapy for severe neurovisceral ASMD should have a broad cellular and tissue impact, since ASM deficiency systemically affects all types of body cells. Our findings show the benefits of FAAHi treatment in all cells and tissues analyzed in ASM-KO mice, including neurons, microglia, astrocytes, and macrophages, and different brain regions and peripheral organs, which, altogether, contribute to the significant extension of the life span. Importantly, an ever-increasing number of intermediate cases between the infantile severe and the chronic visceral forms of ASMD are being diagnosed. This chronic neurovisceral form of the disease (often referred to as Niemann–Pick type A/B) is characterized by slower progression of neurological symptoms and prolonged survival compared to the infantile neurovisceral ASMD. We believe that the neuronal impact of FAAHi treatment may be useful for these patients in which ataxia, gross motor delays, and learning disabilities are commonly seen (McGovern et al., 2017).

Lastly, the feedback loop we have demonstrated herein between SM and CB1 prompted us to ask whether a similar SM-induced CB1 downregulation might occur in other lysosomal storage disorders in which SM accumulates. If so, FAAHi treatment could be appropriate for these diseases as well. Supporting this view, here we observed low CB1 levels in neurons of a mouse model for NPC, in agreement with a recent report in brain tissue (Oddi et al., 2019). We extended this observation to the brain of an NPC patient and showed the efficacy of FAAH inhibition to reduce not only SM levels in NPC patient-derived cells but also cholesterol accumulation, which is a pathologic hallmark of the disease (Devlin et al., 2010). Moreover, acute treatment with high oral doses of a FAAHi showed benefits in the brain of the NPC mouse model. Altogether, these data reinforce the suitability of eCB-enhancing interventions as a potential common treatment for currently fatal sphingolipid storage disorders.

Materials and Methods

Study design

The goal of this study was to characterize alterations in the eCB system and the potential therapeutic value of eCB system enhancement in mouse models and patient-derived cells and tissue of sphingolipid storage disorders. The sample size for each experiment is included in the figure legends. The number of mice used was selected on the basis of previous phenotyping analyses conducted in the same models and calculating the statistical power of the experiment. Mice were genotyped and randomly assigned to the experimental groups. No outliers were excluded in the study. Investigators performing the experiments were blinded to the mouse genotype. Sample collection, treatment, and processing information are included in the Results and Material and Methods sections. Investigators assessing and measuring results were blinded to the intervention.

Antibodies

Antibodies against the following proteins were used in Western blots and for immunofluorescence analysis: calbindin (mouse, Swant, 300, dilution 1:500), CB1 (rabbit, Frontier Institute, AF380, 1:500), CB2 (mouse, R&D Systems, 352110, 1:500), F4/80 (rat, Abcam, ab6640, 1:500), GAPDH (mouse, Abcam, ab8245, 1:5,000), GFAP (mouse, Millipore, MAB3402, 1:1,000), lba1 (rabbit, Wako,
019-19741, 1:500), Lamp1 (rat, DSHB, 1D4B, 1:500), MAP2 (chicken, BioLegend, 822501, 1:500), NSM (rat, Santa Cruz, sc-166637, 1:200), PSD-95 (mouse, BD Transduction Laboratories, 610495, 1:500), and cleaved caspase 3 (Ase 175; rabbit polyclonal, Cell Signaling, 9661, 1:200). HRP-conjugated rabbit anti-mouse or anti-rat and goat anti-rabbit (DakoCytomation) were used as secondary antibodies in Western blots. Alexa-conjugated rabbit anti-mouse or anti-rat and goat anti-rabbit were used as secondary antibodies in immunofluorescence.

CB1 Western blot

Western blots were performed following conventional protocols except for CB1 detection. In this case, samples were sonicated, homogenized in DTT-loading buffer, and loaded without heating into the SDS–PAGE.

Human samples

Formaldehyde-fixed brain tissue from a 3-year-old ASMD patient, a 14-day-old NPC patient, and a 3-year-old control child were donated by the Wylder Nation Foundation (http://wyldernation.org), the Vall d’Hebron Hospital, and the Fundación CIEN Brain Bank (http://bt.fundacioncien.es), respectively.

Primary skin fibroblasts AG07471 (Gerontology Research Center Cell Culture), AG07310 (Collection Baltimore Longitudinal Study on Aging), and GM17912 (Niemann–Pick disease, type C1, NPC1, NPC1 gene; NPC1) were purchased from Coriell Institute for Medical Research (New Jersey, USA).

Informed consent was obtained from all human subjects, and the experiments conformed to the principles set out in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report.

Mice

Breeding colonies were established from ASM heterozygous C57BL/6 mice (Horinouchi et al., 1995) kindly donated by Prof. E.H. Schuchman (Mount Sinai School of Medicine, New York, NY, USA) and from C57BL/6J NPC1<sup>mmf164</sup> mice carrying a D1005G mutation in Npc1 (Maue et al., 2012) purchased from Jackson Laboratories. Animals were grouped by genotype and gender. The mice were kept in a 12-h light/dark cycle in a SPF (specific pathogen free) room. Male/female ASM-KO, Npc1<sup>mmf164</sup>, and WT littermates were analyzed between 1.5 months of age and prolonged for another 8 weeks or until death in the survival experiment. PF or vehicle was administered every 3 days. In the acute study, a single administration of PF or vehicle by oral gavage was given to WT and ASM-KO mice at 4 months of age or to WT and NPC<sup>mmf164</sup> mice at 3 months of age. Mice were sacrificed 48 h after administration.

Immunofluorescence

Cultured neurons at 14 DIV were fixed in 4% PFA 0.12M sucrose and incubated overnight with primary antibodies and subsequently for 1 h with Alexa 488- or Alexa 555-conjugated secondary antibodies. Images were taken using a confocal microscope LSM510 (Zeiss) or LSM800 (Zeiss). The background was subtracted and the image quantified using the Fiji software (Schindelin et al., 2012). The Mander’s coefficient for CB1 co-localization with Lamp1 was obtained by applying the threshold IsoData and using the JACoP plugin.

Mouse brains were dissected, fixed in 4% PFA 0.12M sucrose, and cryoprotected for 24 h in 30% sucrose phosphate buffer saline. The tissue was then frozen in Tissue-Tek optimal cutting temperature compound (Sakura Finetek, Torrance, CA, USA), and 30-μm sagittal sections were obtained with a cryostat (CM 1950 Ag Protect freezing; Leica, Solms, Germany). The sections were incubated overnight at 4°C with the primary antibodies and then with the corresponding Alexa-conjugated secondary antibodies. Finally, the sections were incubated for 10 min with DAPI (Merck) or TOPRO (Thermo Fisher), washed, and mounted with ProLong Gold Antifade (Thermo Fisher). Images were obtained on a confocal LSM710 or LSM800 microscope (Zeiss) and quantified using the Fiji software.

Human sections were deparaffinized in decreasing concentrations of ethanol and xylene and subjected to heat-mediated antigen retrieval in Tris–EDTA buffer (pH 9.0). Afterward, the same protocol
performed for mouse sections was carried out. Finally, sections were dehydrated by immersion in increasing concentrations of ethanol and xylene and mounted using FluorSave (Merck).

**Hematoxylin and eosin staining**

Mouse brain and liver sections were stained using conventional protocols (Feldman & Wolfe, 2014).

**Lipid measurements**

Sphingomyelin levels were measured according to protocols modified from Hojjati and Jiang (2006). Lipid extracts were dried in the presence of Thesit, and SM was converted into peroxide by incubation with sphingomyelinase, alkaline phosphatase, and choline oxidase. Peroxide was measured fluorimetrically in the presence of Thesit, and SM was converted into peroxide by incubation with the third or novel arm closed. After 1 h, mice were placed in the same starting arm with free access to all three arms for 5 min.

**Quantitative RT–PCR**

Total RNA from WT and ASM-KO brains was extracted with the TRIzol Reagent (Ambion/RNA Life Technologies Co.) following the manufacturer’s instructions using the RNaseasy Mini Kit (Qiagen, Hilden, Germany). RNA was quantified by absorbance at 260 nm using a NanoDrop ND-100 (Thermo scientific; Thermo Fisher Scientific Inc.). Retrotranscription to first-strand cDNA was performed using RevertAid H Minus First-Strand cDNA Synthesis Kit (Thermo scientific; Thermo Fisher Scientific Inc.). 10 ng of synthesized cDNA was used to perform fast qPCR using the GoTaq qPCR Master Mix (Promega Co., Madison, WI, USA) in ABI PRISM 7900HT SDS (Applied Biosystems; Life Technologies Co.) following the manufacturer’s instructions. The primers purchased from Sigma-Aldrich (mouse CB1: forward: 5'-GCACCTTCAGGTTCCTG-3' and reverse: 5'-GACTGGCGGAGTGAAAGAT-3'; mouse CB2: forward: 5'-CTACAAAGCTCTAGTCCCGT-3' and reverse: 5'-CCATGAGGCCGCAGGTAAGAAA-3') were used at 0.5 μM final concentration. Three housekeeping genes (Gapdh, GusB, and Pfk1) were used as endogenous controls.

**Behavioral tests**

The rotarod test was performed in an accelerating rotarod apparatus (Ugo Basile, Varese, Italy), on which the mice were trained for 2 days at a constant speed: the first day—four times at 4 r.p.m. for 1 min; and on the second day—four times at 8 r.p.m. for 2 min. On the third day, the rotarod was set to progressively accelerate from 4 to 40 r.p.m. for 5 min, and the mice were tested four times. During the accelerating trials, the latency to fall from the rod was measured.

The Y-maze was performed as previously described (Cognato et al., 2010). During the first training trial (lasting 7 min), the mice only explored two arms (the initial arm and one other arm), maintaining the third or novel arm closed. After 1 h, mice were placed in the same starting arm with free access to all three arms for 5 min.

The time spent in the novel arm was counted and expressed as a percentage of the total exploration time.

The tail suspension test (Can et al., 2012) was performed by suspending the mice through the tail over a 6-min period. The time in which the animals were immobile was measured and expressed as percentage of the total time.

The elevated plus maze was performed as described (Lister, 1987). Each mouse was placed in the central square of the maze facing one of the closed arms and was recorded for 5 min. The time spent in the open arms of the maze was measured and expressed as a percentage of the total time.

**Statistical analysis**

Data from at least three different experimental groups were quantified and presented as the mean ± SEM. Normality of the data was tested using the Shapiro–Wilks test. For two-group comparisons, the Mann–Whitney U-test for non-parametric data or a two-sample Student’s t-test for data with parametric distribution was used. For multiple comparisons, data with a normal distribution were analyzed by one-way ANOVA followed by Bonferroni, Tukey, or Games–Howell post hoc test. The statistical significance of non-parametric data was determined by the Kruskal–Wallis test to analyze all experimental groups. The Mann–Whitney U-test was used to analyze paired genotypes, applying the Bonferroni correction. Linear regression test with 95% confidence interval was used to analyze slope differences. P-values (P) < 0.05 were considered significant. In the figures, asterisks indicate the P-values: *< 0.05; **< 0.005; ***< 0.001. GraphPad Prism 5.0 software (GraphPad Software, La Jolla, CA, USA) was used for all statistical analysis.

**Data and software availability**

This study includes no data deposited in external repositories.

The paper explained

**Problem**

Acid sphingomyelinase deficiency (ASMD) and Niemann–Pick type C (NPC) are fatal lysosomal storage disorders in which lipids like sphingomyelin accumulate in cells leading to severe neurological involvement and early death.

**Results**

Here, we describe the sphingomyelin-induced downregulation of the eCB receptor CB2 in neurons of mouse models and patients of these diseases. Enhancement of the eCB system by oral treatment with inhibitors of the eCB-degrading enzyme fatty acid amide hydrolase (FAAH), reduced lipid storage, prevented neurodegeneration, and increased life span in the mouse models.

**Impact**

These results discover a novel therapeutic target and a non-invasive strategy for ASMD and NPC with potential for the treatment of other sphingolipid storage disorders.

**The Authors**

Adrián Bartoll et al.

**EMBO Molecular Medicine**

© 2020 The Authors

EMBO Molecular Medicine e11776 | 2020 17 of 20

**Expanded View** for this article is available online.
Acknowledgements

We are grateful to Steven Laffoon and the Wylder Nation Foundation (www.wyldernation.org) for the continuous support. We thank Dr. Melissa Wasserstein at the Children’s Hospital at Montefiore for insightful comments and Dr. A. Rabano at the Fundación Cien and Dr. E. Martínez-Sáez at the Hospital Vall d’Hebron for donating brain samples. We also thank the microscope facility at the CBM50 for their assistance with the confocal imaging and the institutional support of the Fundación Ramón Areces to the CBM50. This work was funded by the Wylder Nation Foundation and by grants from the Spanish Ministry of Science and Education (SAF2017-87698-R) (AEI/FEDER, UE) to M.D.L and a MERIT award from the National Institutes of Health (2R37HD028607) to E.H.S.

Author contributions

AB and AT-Z designed, performed, and analyzed the experiments. JC measured eCB levels. MG and EHS reviewed the data and provided advice. MDL designed the experiments, analyzed the data, and wrote the manuscript.

Conflict of interest

MDL, AB, and EHS are co-inventors on a patent describing the use of FAAHi for the treatment of lysosomal storage diseases.

References


Paugh SW, Cassidy MP, He H, Milsen S, Sim-Selley LJ, Spiegel S, Selley DE (2006) Sphingosine and its analog, the immunosuppressant 2-amino-2-[4-octylphenyl(ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor. Mol Pharmacol 70: 41 – 50
